Method and apparatus for creating a bi-polar virtual electrode used for the ablation of tissue

Abstract
A method and apparatus for creating a virtual electrode to ablate bodily tissue. The apparatus includes an outer tube, a first electrode, an inner tube and a second electrode. The outer tube is fluidly connected to a source of conductive fluid and defines a proximal end and a distal end. The distal end includes an opening for delivering conductive fluid from the outer tube. The first electrode is disposed at the distal end of the outer tube for applying a current to conductive fluid delivered from the outer tube. The inner tube is coaxially received within the outer tube and is connected to a source of conductive fluid. The inner tube defines a proximal end and a distal end, with the distal end forming an opening for delivering conductive fluid from the inner tube. Finally, the second electrode is disposed at the distal end of the inner tube for applying a current to conductive fluid delivered from the inner tube. With this configuration, upon final assembly, the distal end of the outer tube is axially spaced from the distal end of the inner tube such that the first electrode is spaced from the second electrode. As a result, a bi-polar virtual electrode can be established.
Description
FIELD OF THE INVENTION

The present invention relates generally to an apparatus for creating a virtual electrode. More particularly, the present invention relates to an apparatus for the creation of a virtual electrode that is useful for the ablation of soft tissue and neoplasms.


BACKGROUND OF THE PRESENT INVENTION

The utilization of an electric current to produce an ameliorative effect on a bodily tissue has a long history, reportedly extending back to the ancient Greeks. The effects on bodily tissue from an applied electric current, and thus the dividing line between harmful and curative effects, will vary depending upon the voltage levels, current levels, the length of time the current is applied, and the tissue involved. One such effect resulting from the passage of an electric current through tissue is heat generation.


Body tissue, like all non-superconducting materials, conducts current with some degree of resistance. This resistance creates localized heating of the tissue through which the current is being conducted. The amount of heat generated will vary with the power P deposited in the tissue, which is a function of the product of the square of the current I and the resistance R of the tissue to the passage of the current through it (P=I2R.).


As current is applied to tissue, then, heat is generated due to the inherent resistance of the tissue. Deleterious effects in the cells making up the tissue begin to occur at about 42° Celsius. As the temperature of the tissue increases due to heat generated by the tissue□s resistance, the tissue will undergo profound changes and eventually, as the temperature becomes high enough, that is, generally greater than 45° C., the cells will die. The zone of cell death is known as a lesion and the procedure followed to create the lesion is commonly called an ablation. As the temperature increases beyond cell death temperature, complete disintegration of the cell walls and cells caused by boiling off of the tissue's water can occur. Cell death temperatures can vary somewhat with the type of tissue to which the power is being applied, but generally will begin to occur within the range of 45° to 60° C., though actual cell death of certain tissue cells may occur at a higher temperature.


In recent times, electric current has found advantageous use in surgery, with the development of a variety of surgical instruments for cutting tissue or for coagulating blood. Still more recently, the use of alternating electric current to ablate, that is, kill, various tissues has been explored. Typically, current having a frequency from about 3 kilohertz to about 300 gigahertz, which is generally known as radiofrequency or radiofrequency (RF) current, is used for this procedure. Destruction, that is, killing, of tissue using an RF current is commonly known as radiofrequency ablation. Often radiofrequency ablation is performed as a minimally invasive procedure and is thus known as radiofrequency catheter ablation because the procedure is performed through and with the use of a catheter. By way of example, radiofrequency catheter ablation has been used to ablate cardiac tissue responsible for irregular heart beats or arrythmias.


The prior art applications of current to tissue have typically involved applying the current using a dry electrode. That is, a metal electrode is applied to the tissue desired to be affected and a generated electric current is passed through the electrode to the tissue. A commonly known example of an instrument having such an operating characteristic is an electrosurgical instrument known as a bovie knife. This instrument includes a cutting/coagulating blade electrically attached to a current generator. The blade is applied to the tissue of a patient and the current passes through the blade into the tissue and through the patients body to a metal base electrode or ground plate usually placed underneath and in electrical contact with the patient. The base electrode is in turn electrically connected to the current generator so as to provide a complete circuit.


As the current from the bovie knife passes from the blade into the tissue, the resistance provided by the tissue creates heat. In the cutting mode, a sufficient application of power through the bovie knife to the tissue causes the fluid within the cell to turn to steam, creating a sufficient overpressure so as to burst the cell walls. The cells then dry up, desiccate, and carbonize, resulting in localized shrinking and an opening in the tissue. Alternatively, the bovie knife can be applied to bleeding vessels to heat and coagulate the blood flowing therefrom and thus stop the bleeding.


As previously noted, another use for electrical instruments in the treatment of the body is in the ablation of tissue. To expand further on the brief description given earlier of the ablation of cardiac tissue, it has long been known that a certain kind of heart tissue known as sino-atrial and atrio-ventricular nodes spontaneously generate an electrical signal that is propagated throughout the heart along conductive pathways to cause it to beat. Occasionally, certain heart tissue will misfire, causing the heart to beat irregularly. If the errant electrical pathways can be determined, the tissue pathways can be ablated and the irregular heartbeat remedied. In such a procedure, an electrode is placed via a catheter into contact with the tissue and then current is applied to the tissue via the electrode from a generator of RP current. The applied current will cause the tissue in contact with the electrode to heat. Power will continue to be applied until the tissue reaches a temperature where the heart tissue dies, thereby destroying the errant electrical pathway and the cause of the irregular heartbeat.


Another procedure using RF ablation is transurethral needle ablation, or TUNA, which is used to create a lesion in the prostate gland for the treatment of benign prostatic hypertrophy (BPI) or the enlargement of the prostate gland. In a TUNA procedure, a needle having an exposed conductive tip is inserted into the prostate gland and current is applied to the prostate gland via the needle. As noted previously, the tissue of the prostate gland heats locally surrounding the needle tip as the current passes from the needle to the base electrode. A lesion is created as the tissue heats and the destroyed cells may be reabsorbed by the body, infiltrated with scar tissue, or just become non-functional.


While there are advantages and uses for such dry electrode instruments, there are also several notable disadvantages. One of these disadvantages is that during a procedure, coagulum—dried blood cells and tissue cells—will form on the electrode engaging the tissue. Coagulum acts as an insulator and effectively functions to prevent current transfer from the blade to the tissue. This coagulum insulation can be overcome with more voltage so as to keep the current flowing, but only at the risk of arcing and injuring the patient. Thus, during surgery when the tissue is cut with an electrosurgical scalpel, a build-up of coagulated blood and desiccated tissue will occur on the blade, requiring the blade to be cleaned before further use. Typically, cleaning an electrode/scalpel used in this manner will involve simply scraping the dried tissue from the electrode/scalpel by rubbing the scalpel across an abrasive pad to remove the coagulum. This is a tedious procedure for the surgeon and the operating staff since it requires the real work of the surgery to be discontinued while the cleaning operation occurs. This procedure can be avoided with the use of specially coated blades that resist the build up of coagulum. Such specialty blades are costly, however.


A second disadvantage of the dry electrode approach is that the electrical heating of the tissue creates smoke that is now known to include cancer-causing agents. Thus, preferred uses of such equipment will include appropriate ventilation systems, which can themselves become quite elaborate and quite expensive.


A further, and perhaps the most significant, disadvantage of dry electrode electrosurgical tools is revealed during cardiac ablation procedures. During such a procedure, an electrode that is otherwise insulated but having an exposed, current carrying tip is inserted into the heart chamber and brought into contact with the inner or endocardial side of the heart wall where the ablation is to occur. The current is initiated and passes from the current generator to the needle tip electrode and from there into the tissue so that a lesion is created. Typically, however, the lesion created by a single insertion is insufficient to cure the irregular heartbeat because the lesion created is of an insufficient size to destroy the errant electrical pathway. Thus, multiple needle insertions and multiple current applications are almost always required to ablate the errant cardiac pathway, prolonging the surgery and thus increasing the potential risk to the patient.


This foregoing problem is also present in TUNA procedures, which similarly require multiple insertions of the needle electrode into the prostate gland. Failing to do so will result in the failure to create a lesion of sufficient size otherwise required for a beneficial results. As with radiofrequency catheter ablation of cardiac tissue, then, the ability to create a lesion of the necessary size to alleviate BPH symptoms is limited and thus requires multiple insertions of the electrode into the prostate.


A typical lesion created with a dry electrode using RF current and a single insertion will normally not exceed one centimeter in diameter. This small size-often too small to be of much or any therapeutic benefit—stems from the fact that the tissue surrounding the needle electrode tends to desiccate as the temperature of the tissue increases, leading to the creation of a high resistance to the further passage of current from the needle electrode into the tissue, all as previously noted with regard to the formation of coagulum on an electrosurgical scalpel. This high resistance—more properly termed impedance since typically an alternating current is being used—between the needle electrode and the base electrode is commonly measured by the RP current generator. When the measured impedance reaches a predetermined level, the generator will discontinue current generation. Discontinuance of the ablation procedure under these circumstances is necessary to avoid injury to the patient.


Thus, a typical procedure with a dry electrode may involve placing the needle electrode at a first desired location; energizing the electrode to ablate the tissue; continue applying current until the generator measures a high impedance and shuts down; moving the needle to a new location closely adjacent to the first location; and applying current again to the tissue through the needle electrode. This cycle of electrode placement, electrode energization, generator shut down, electrode re-emplacement, and electrode re-energization, will be continued until a lesion of the desired size has been created. As noted, this increases the length of the procedure for the patient. Additionally, multiple insertions increases the risk of at least one of the placements being in the wrong location and, consequently, the risk that healthy tissue may be undesirably affected while diseased tissue may be left untreated. The traditional RF ablation procedure of using a dry ablation therefore includes several patient risk factors that both patient and physician would prefer to reduce or eliminate.


The therapeutic advantages of RF current could be increased if a larger lesion could be created safely with a single positioning of the current-supplying electrode. A single positioning would allow the procedure to be carried out more expeditiously and more efficiently, reducing the time involved in the procedure. Larger lesions can be created in at least two ways. First, simply continuing to apply current to the patient with sufficiently increasing voltage to overcome the impedance rises will create a larger lesion, though almost always with undesirable results to the patient. Second, a larger lesion can be created if the current density, that is, the applied electrical energy, could be spread more efficiently throughout a larger volume of tissue. Spreading the current density over a larger tissue volume would correspondingly cause a larger volume of tissue to heat in the first instance. That is, by spreading the applied power throughout a larger tissue volume, the tissue would heat more uniformly over a larger volume, which would help to reduce the likelihood of generator shutdown due to high impedance conditions. The applied power, then, will cause the larger volume of tissue to be ablated safely, efficiently, and quickly.


Research conducted under the auspices of the assignee of the present invention has focused on spreading the current density throughout a larger tissue volume through the creation, maintenance, and control of a virtual electrode within or adjacent to the tissue to be ablated. A virtual electrode can be created by the introduction of a conductive fluid, such as isotonic or hypertonic saline, into or onto the tissue to be ablated. The conductive fluid will facilitate the spread of the current density substantially equally throughout the extent of the flow of the conductive fluid, thus creating an electrode—a virtual electrode—substantially equal in extent to the size of the delivered conductive fluid. RF current can then be passed through the virtual electrode into the tissue.


A virtual electrode can be substantially larger in volume than the needle tip electrode typically used in RF interstitial ablation procedures and thus can create a larger lesion than can a dry, needle tip electrode. That is, the virtual electrode spreads or conducts the RF current density outward from the RF current source—such as a current carrying needle, forceps or other current delivery device—into or onto a larger volume of tissue than is possible with instruments that rely on the use of a dry electrode. Stated otherwise, the creation of the virtual electrode enables the current to flow with reduced resistance or impedance throughout a larger volume of tissue, thus spreading the resistive heating created by the current flow through a larger volume of tissue and thereby creating a larger lesion than could otherwise be created with a dry electrode.


While the efficacy of RP current ablation techniques using a virtual electrode has been demonstrated in several studies, the currently available instruments useful in such procedures lags behind the research into and development of hoped-for useful treatment modalities for the ablation of soft tissue and malignancies.


It would be desirable to have an apparatus capable of creating a virtual electrode for the controlled application of tissue ablating RF electric current to a tissue of interest so as to produce a lesion of desired size and configuration.


SUMMARY OF THE INVENTION

One aspect of the present invention provides a surgical apparatus for creating a virtual electrode to ablate bodily tissue. The surgical apparatus comprises an outer tube, a first electrode, an inner tube and a second electrode. The outer tube is fluidly connected to a source of conductive fluid and defines a proximal end and a distal end. In this regard, the distal end of the outer tube includes an opening for delivering a conductive fluid from the outer tube. The first electrode is disposed at the distal end of the outer tube and is configured to apply a current to conductive fluid delivered from the outer tube. The inner tube is coaxially received within the outer tube. The inner tube is fluidly connected to a source of conductive fluid and defines a proximal end and a distal end. In this regard, the distal end of the inner tube forms an opening for delivering a conductive fluid from the inner tube. The second electrode is disposed at the distal end of the inner tube. The second electrode is configured to apply a current to conductive fluid delivered from the inner tube. Upon final assembly, the distal end of the outer tube is axially spaced from the distal end of the inner tube such that the first electrode is spaced from the second electrode. With this configuration, then, a bi-polar virtual electrode can be established.


Another aspect of the present invention provides a surgical system for creating a virtual electrode to ablate bodily tissue. The surgical system includes a fluid source, a current source, and a surgical instrument. The fluid source maintains a supply of conductive fluid. The current source is configured to selectively supply an electrical current. The surgical instrument includes an outer tube, a first electrode, an inner tube and a second electrode. The outer tube is fluidly connected to the fluid source and defines a proximal end and a distal end. The distal end of the outer tube includes an opening for delivering the conductive fluid. The first electrode is disposed at the distal end of the outer tube and is electrically connected to the current source. The inner tube is coaxially received within the outer tube and is fluidly connected to the fluid source. The inner tube defines a proximal end and a distal end, with the distal end of the inner tube forming an opening for delivering the conductive fluid. The second electrode is disposed at the distal end of the inner tube and is electrically connected to the current source. Upon final assembly, the distal end of the outer tube is spaced from the distal end of the inner tube such that the conductive fluid is delivered as a first bolus from the outer tube and a second bolus from the inner tube. Current is applied to the first and second boluses by the first and second electrodes, respectively. With this configuration, a bi-polar virtual electrode can be created.


Another aspect of the present invention relates to a method for ablating bodily tissue at a target site. The method includes delivering a first bolus of a conductive fluid at the target site. A second bolus of conductive fluid is also delivered at the target site, the second bolus being spaced from the first bolus. Finally, a current is substantially simultaneously applied to each of the first bolus and the second bolus to create a virtual electrode, ablating tissue in contact with the first and second boluses. In one preferred embodiment, tissue between the first and second boluses is collapsed prior to applying the current.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a block diagram of a system for creating a virtual electrode in accordance with the present invention;



FIG. 2 is a perspective view, with a portion cut away, of a surgical apparatus in accordance with the present invention; and



FIG. 3 is a schematic view of a portion of the surgical apparatus of FIG. 2 ablating bodily tissue.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


FIG. 1 illustrates in block form a system 10 for RF ablation useful with the present invention. The system 10 includes a current source of radiofrequency alternating electric current 12, a fluid source of RF ablating fluid 14, including but not limited to saline and other conductive solutions, and a surgical instrument 16 for delivering RF current and ablation fluid to a tissue site (not shown) for ablation purposes. In one preferred embodiment, the surgical instrument 16 is connected to the current source 12 and the fluid source 14. It will be understood that the current source 12 and the fluid source 14 may be combined into a single operational structure controlled by an appropriate microprocessor for a controlled delivery of ablating fluid and a controlled application of RF current, both based upon measured parameters such as but not limited to, flow rate, tissue temperature at the ablation site and at areas surrounding the ablation site; impedance, the rate of change of the impedance, the detection of arcing between the surgical instrument and the tissue, the time period during which the ablation procedure has been operating, and additional factors as desired.


While the surgical instrument 16 is shown as being connected to both the current source 12 and the fluid source 14, the present system is not so limited but could include separate needles or other instruments useful in RF liquid ablation procedures, that is, for example, a single straight or coiled needle having an exposed end and a fluid flow path there through could be used to deliver both fluid and current to the target tissue for ablation purposes. Alternatively, a separate needle could be used to deliver the current and a separate needle or needles could be used to deliver fluid to the target tissue. In addition, the application of the present system is not limited to the use of straight needles or helical needles as surgical instruments but could find use with any type of instrument wherein a conductive solution is delivered to a tissue and an RF current is applied to the tissue through the conductive fluid. Such instruments thus would include straight needles, helical needles, forceps, roller balls, instruments for the treatment of vascular disorders, and any other instrument.


In one preferred embodiment, the system 10 further includes a second fluid source 18 for delivery of tissue protecting fluid, via a delivery instrument 20, to a tissue whose ablation is not desired.


The surgical instrument 16 may assume a wide variety of forms. One preferred embodiment of a surgical apparatus 50 is shown in FIG. 2. The apparatus 50 generally includes a bi-polar electrode that is useful in an ablation procedure using an RF ablating fluid such as, but not limited to, isotonic or hypertonic saline. Further, the apparatus 50 generally includes a plurality of coaxial thin walled tubes forming a catheter delivery system for RF ablating fluid and RF ablating current. Thus, the apparatus 50 preferably includes a first or outer thin walled tube 52 having a proximally attached hemostasis valve 54. The valve 54 includes an inlet 56 for RF ablating fluid flow as indicated by arrow 58 and also an access port 60 for an electrical line 62, which can be electrically connected to the RP current source 12 (FIG. 1). A distal end of the first tube 52 may be provided with one or more thermocouples or other temperature sensors 64. The distal end of the first tube 52 also includes an electrode 66 which is electrically connected to the line 62, thereby providing one of the two bi-polar electrodes envisioned by a preferred embodiment of the present invention. It will be understood that the first tube 52 is electrically insulated or otherwise non-conductive. The first tube 52 provides a flow passage for the RF ablating fluid from the fluid source 14 (FIG. 1) to the distal end of the first tube 52 where it exits the first tube 52 as indicated by arrows 68.


The apparatus 50 further includes a second or intermediate thin walled tube 70 coaxially disposed within the first tube 52. The second tube 70 has a proximally attached hemostasis valve 72. The valve 72 includes a suction port 74 for directing fluid flow as indicated by arrow 76. A distal end of the second tube 70 may be provided with one or more vacuum apertures 78 through which a suction is applied to surrounding tissue (not shown), via a vacuum formed at the suction port 74. Thus, applying suction to the suction port 74 will draw the surrounding tissue into contact with the vacuum apertures 78 and the distal end of the second tube 70. In addition, with this same process, some RF ablating fluid may be removed via the applied suction as indicated by arrows 80.


The apparatus 50 further includes a third or inner thin walled tube 82 coaxially disposed within the second tube 70. The third tube 82 has a proximally attached hemostasis valve 84. The valve 84 includes an inlet 84 for RF ablating fluid flow as indicated by arrow 86 and also an access port 88 for an electrical line 90, which can be electrically connected to the current source 12 (FIG. 1). A distal end of the third tube 82 also includes an electrode 92, which is electrically connected to the line 90, thereby providing the other one of the two bi-polar electrodes envisioned by a preferred embodiment of the present invention. It will be understood that the third tube 82 is electrically insulated or otherwise non-conductive. THE third tube 82 provides a flow passage for the RF ablating fluid from the fluid source 14 (FIG. 1) to the distal end of the third tube 82 where it exits the third tube 82 as indicated by arrows 94.


The surgical apparatus 50 may further include a probe 100 that extends through an interior passage of the third tube 82 and that is freely movable therewithin. The probe 100 may include a thermocouple 102 disposed at a most distal end thereof and may be connected via an electrical line 104 to the RF current source 12 (FIG. 1) to provide a temperature measurement at a predetermined distance from the electrodes 66 and 92.


In operation, following delivery to a particular target site, RP ablating fluid will be provided to the ports 56 and 84 from the fluid source 14 (FIG. 1). The fluid will exit the distal ends of the first tube 52 and the third tube 82, respectively, and begin to form boluses of fluid along or within the tissue at the target site. Application of a suction at the vacuum aperture 78, via the suction port 74, will cause the tissue surrounding the distal end of the second tube 70 to be collapsed or pulled into a substantially fluid tight relationship with the second tube 70, thereby preventing migration of the fluid, in particular via a capillary effect, along the second tube 70 between the distal ends of the first and third tubes 52, 82. RF ablating power can be applied and an ablation procedure can be carried out. By the application of suction to the tissue and the prevention of the flow of fluid along the second tube 70, shorting of the current between the electrodes 66 and 92 can be avoided.



FIG. 3 represents schematically the fluid flow and current flow achieved during use of the present invention. Thus, FIG. 3 shows a tissue 110, such as liver, into which a portion of the surgical apparatus 50 has been inserted. Infusion of the RP ablating fluid will initially create two separate boluses of fluid, 112 and 114. If not for the suction applied to the tissue surrounding vacuum apertures 78, fluid would tend to travel along the path created during insertion and placement of the apparatus 50 in the tissue 110. Applying suction intermediate the release of the fluid, however, prevents such fluid travel and substantially prevents any shortage between the electrodes 66, 92 directly therebetween. The applied current can thus spread readily through the boluses 112, 114 and then travel therebetween as indicated by the lines 116. In this way, then, ablation can be accomplished between the bi-polar electrodes 66 and 92. The lesion created with the use of such a bi-polar structure will essentially be the size of the boluses 112, 114 at a minimum, though it will be understood that cell-to-cell thermal conduction will occur that will make the lesion in reality larger than the boluses 112, 114, assuming that power is left on for the appropriate length of time.


As is well known, when an electro-surgical tool is used, or for that matter, any electrical device, a complete circuit for current flow must be provided. Thus, when a monopolar surgical instrument such as a bovie knife is used, a ground pad connected to the RF current generator is placed under the patient to provide a complete electrical circuit from the generator, to the knife, through the patient to the ground pad, and back to the generator. With the present invention, no ground pad is needed. The current flows from the current source 12 (FIG. 1) to one of the two electrodes 66 or 92 on the apparatus 50, through the patient to the other electrode 66 or 92, and then back to the current source 12. Such bi-polar structure enables the physician to localize the effect of the current passing through the patient, thereby avoiding certain risks associated with the use of a monopolar device, including but not limited to the risk of burns where the ground pad contacts the patient. Additionally, by controlling the relative spacing between the two electrodes 66, 92 of a bi-polar instrument, the size of the lesion can be controlled. Thus, where the electrodes 66, 92 are close to each other, there will be little tissue between them through which the current will travel and the lesion size will be reduced relative to an instrument where the electrodes are spaced relatively farther apart. In addition, the shape of the lesion is somewhat controllable by controlling both the fluid flow and the spacing of the electrodes 66, 92. It will be understood that regardless of the device used that the lesion size and shape is a product of many factors, including the tissue composition, the conductivity of the fluid, the amount of applied current, the amount of cell-to-cell thermal conductivity, the time period the current is applied, tissue temperature, and fluid temperature when applied, among others.


Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.

Claims
  • 1. A method for ablating tissue comprising: positioning an ablating element of an ablation device adjacent to the tissue, wherein the ablation device comprises: an ablation member comprising an elongated tubular member, wherein the ablating element is disposed at a distal end portion of the ablation member; anda suction member comprising an elongated tubular member having a lumen in fluid communication with a vacuum and a vacuum opening disposed at a distal end portion of the suction member, the suction member coupled to the ablation member, wherein at least a portion of the elongated tubular member of the ablation member resides within the suction member lumen and the vacuum opening;providing suction to the tubular suction member to draw the tissue into contact with the device; andproviding an ablation energy to the ablating element for ablating the tissue.
  • 2. The method of claim 1, wherein the ablation energy comprises electric current.
  • 3. The method of claim 1, wherein the ablation energy comprises radiofrequency energy provided from a radiofrequency generator.
  • 4. The method of claim 1, wherein suction is provided from a vacuum source.
  • 5. The method of claim 1, wherein the ablating element comprises an electrode.
  • 6. The method of claim 1, wherein the ablation device further comprises a temperature sensor.
  • 7. The method of claim 6, further comprises measuring a temperature with the temperature sensor.
  • 8. A method for ablating tissue comprising: positioning adjacent the tissue an ablating member of an ablation device, the device comprising: an elongated cylindrical ablation member comprising a tubular member and an ablating member disposed at a distal end portion of the ablation member; andan elongated cylindrical suction member comprising a tubular member having a lumen in fluid communication with a vacuum and a vacuum opening disposed at a distal end portion of the suction member, the suction member coupled to the ablation member, wherein at least a portion of the ablation member passes through the lumen and the vacuum opening;providing suction to the suction member to draw the tissue into contact with the device; andproviding an ablation energy to the ablating member for ablating the tissue.
  • 9. The method of claim 8, wherein the ablating member comprises an electrode.
  • 10. The method of claim 8, wherein the ablation device further comprises a temperature sensor.
  • 11. The method of claim 10, further comprising measuring a temperature with the temperature sensor.
Parent Case Info

This patent application is a continuation of U.S. patent application Ser. No. 11/636,331, filed Dec. 8, 2006, now abandoned, which is a continuation of U.S. patent application Ser. No. 11/229,414, filed Sep. 16, 2005, now U.S. Pat. No. 7,156,845, which is a continuation of U.S. patent application Ser. No. 10/754,768, filed Jan. 8, 2004, now U.S. Pat. No. 6,962,589, which is a continuation of U.S. patent application Ser. No. 09/865,591, filed May 25, 2001, now U.S. Pat. No. 6,706,039, which is a continuation of U.S. patent application Ser. No. 09/347,971, filed Jul. 6, 1999, now U.S. Pat. No. 6,238,393, which claimed the benefit of U.S. Provisional Application No. 60/091,929, filed on Jul. 7, 1998.

US Referenced Citations (385)
Number Name Date Kind
2275167 Bierman Mar 1942 A
3736936 Basiulis et al. Jun 1973 A
3807403 Stumpf et al. Apr 1974 A
3823575 Parel Jul 1974 A
3823718 Tromovitch Jul 1974 A
3827436 Stumpf et al. Aug 1974 A
3830239 Stumpf Aug 1974 A
3859986 Okada et al. Jan 1975 A
3862627 Hans, Sr. Jan 1975 A
3886945 Stumpf et al. Jun 1975 A
3907339 Stumpf et al. Sep 1975 A
3910277 Zimmer Oct 1975 A
3913581 Ritson et al. Oct 1975 A
3924628 Droegemueller et al. Dec 1975 A
4018227 Wallach Apr 1977 A
4022215 Benson May 1977 A
4061135 Widran et al. Dec 1977 A
4063560 Thomas et al. Dec 1977 A
4072152 Linehan Feb 1978 A
4082096 Benson Apr 1978 A
4207897 Lloyd et al. Jun 1980 A
4248224 Jones Feb 1981 A
4275734 Mitchiner Jun 1981 A
4278090 van Gerven Jul 1981 A
4377168 Rzasa et al. Mar 1983 A
4519389 Gudkin et al. May 1985 A
4598698 Siegmund Jul 1986 A
4601290 Effron et al. Jul 1986 A
4664110 Schanzlin May 1987 A
4736749 Lundback Apr 1988 A
4779611 Grooters et al. Oct 1988 A
4802475 Weshahy Feb 1989 A
4815470 Curtis et al. Mar 1989 A
4832048 Cohen May 1989 A
4872346 Kelly-Fry et al. Oct 1989 A
4916922 Mullens Apr 1990 A
4917095 Fry et al. Apr 1990 A
4936281 Stasz Jun 1990 A
4946460 Merry et al. Aug 1990 A
4976711 Parins et al. Dec 1990 A
5013312 Parins et al. May 1991 A
5029574 Shimamura et al. Jul 1991 A
5044165 Linner et al. Sep 1991 A
5078713 Varney Jan 1992 A
5080102 Dory Jan 1992 A
5080660 Buelina Jan 1992 A
5100388 Behl et al. Mar 1992 A
5108390 Potocky et al. Apr 1992 A
5147355 Freidman et al. Sep 1992 A
5178133 Pena Jan 1993 A
5197963 Parins Mar 1993 A
5207674 Hamilton May 1993 A
5217860 Fahy et al. Jun 1993 A
5222501 Ideker et al. Jun 1993 A
5224943 Goddard Jul 1993 A
5228923 Hed Jul 1993 A
5231995 Desai Aug 1993 A
5232516 Hed Aug 1993 A
5254116 Baust et al. Oct 1993 A
5263493 Avitall Nov 1993 A
5269291 Carter Dec 1993 A
5275595 Dobak, III Jan 1994 A
5277201 Stern Jan 1994 A
5281213 Milder et al. Jan 1994 A
5281215 Milder Jan 1994 A
5295484 Marcus et al. Mar 1994 A
5309896 Moll et al. May 1994 A
5316000 Chapelon et al. May 1994 A
5317878 Bradshaw et al. Jun 1994 A
5318525 West et al. Jun 1994 A
5322520 Milder Jun 1994 A
5323781 Ideker et al. Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5324284 Imran Jun 1994 A
5324286 Fowler Jun 1994 A
5334181 Rubinsky et al. Aug 1994 A
5334193 Nardella Aug 1994 A
5348554 Imran et al. Sep 1994 A
5353783 Nakao et al. Oct 1994 A
5354258 Dory Oct 1994 A
5361752 Moll et al. Nov 1994 A
5385148 Lesh et al. Jan 1995 A
5396887 Imran Mar 1995 A
5397304 Truckai Mar 1995 A
5400770 Nakao et al. Mar 1995 A
5400783 Pomeranz et al. Mar 1995 A
5403309 Coleman et al. Apr 1995 A
5403311 Abele et al. Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5409483 Campbell et al. Apr 1995 A
5423807 Mlilder Jun 1995 A
5423811 Imran et al. Jun 1995 A
5427119 Swartz et al. Jun 1995 A
5431649 Mulier et al. Jul 1995 A
5433708 Nichols et al. Jul 1995 A
5435308 Gallup et al. Jul 1995 A
5437651 Todd et al. Aug 1995 A
5443463 Stern et al. Aug 1995 A
5443470 Stern et al. Aug 1995 A
5450843 Moll et al. Sep 1995 A
5452582 Longsworth Sep 1995 A
5452733 Sterman et al. Sep 1995 A
5458596 Lax et al. Oct 1995 A
5458597 Edwards et al. Oct 1995 A
5462545 Wang et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5469853 Law et al. Nov 1995 A
5472876 Fahy Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5478330 Imran et al. Dec 1995 A
5486193 Bourne et al. Jan 1996 A
5487385 Avitall Jan 1996 A
5487757 Truckai et al. Jan 1996 A
5496312 Klicek Mar 1996 A
5497774 Swartz et al. Mar 1996 A
5498248 Milder Mar 1996 A
5500012 Brucker et al. Mar 1996 A
5505730 Edwards Apr 1996 A
5516505 McDow May 1996 A
5520682 Baust et al. May 1996 A
5522870 Ben-Zion Jun 1996 A
5536267 Edwards et al. Jul 1996 A
5542928 Evans et al. Aug 1996 A
5545195 Lennox et al. Aug 1996 A
5545200 West et al. Aug 1996 A
5549661 Kordis et al. Aug 1996 A
5555883 Avitall Sep 1996 A
5558671 Yates Sep 1996 A
5560362 Sliwa, Jr. et al. Oct 1996 A
5562720 Stern et al. Oct 1996 A
5569241 Edwards Oct 1996 A
5571088 Lennox et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5573532 Chang et al. Nov 1996 A
5575766 Swartz et al. Nov 1996 A
5575788 Baker et al. Nov 1996 A
5575810 Swanson et al. Nov 1996 A
5578007 Imran Nov 1996 A
5582609 Swanson et al. Dec 1996 A
5584872 LaFontaine et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5590657 Cain et al. Jan 1997 A
5595183 Swanson et al. Jan 1997 A
5607462 Imran Mar 1997 A
5609151 Mulier Mar 1997 A
5617854 Munsif Apr 1997 A
5630837 Crowley May 1997 A
5637090 McGee et al. Jun 1997 A
5643197 Brucker et al. Jul 1997 A
5653692 Masterson et al. Aug 1997 A
5656029 Imran et al. Aug 1997 A
5658278 Imran et al. Aug 1997 A
5671747 Connor Sep 1997 A
5673695 McGee et al. Oct 1997 A
5676662 Fleischhacker et al. Oct 1997 A
5676692 Sanghvi et al. Oct 1997 A
5676693 Lafontaine Oct 1997 A
5678550 Bassen et al. Oct 1997 A
5680860 Imran Oct 1997 A
5681278 Igo et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5683384 Gough et al. Nov 1997 A
5687723 Avitall Nov 1997 A
5687737 Branham et al. Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5690611 Swartz et al. Nov 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5697925 Taylor Dec 1997 A
5697927 Imran et al. Dec 1997 A
5697928 Walcott et al. Dec 1997 A
5713942 Stern Feb 1998 A
5716389 Walinsky et al. Feb 1998 A
5718241 Ben-Haim et al. Feb 1998 A
5718701 Shai et al. Feb 1998 A
5720775 Lanard Feb 1998 A
5722402 Swanson et al. Mar 1998 A
5725524 Mulier et al. Mar 1998 A
5730074 Peter Mar 1998 A
5730127 Avitall Mar 1998 A
5730704 Avitall Mar 1998 A
5733280 Avitall Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5735290 Sterman et al. Apr 1998 A
5755760 Maguire et al. May 1998 A
5769846 Edwards et al. Jun 1998 A
5782828 Chen et al. Jul 1998 A
5785706 Bednarek Jul 1998 A
5788636 Curley Aug 1998 A
5792140 Tu et al. Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5800428 Nelson et al. Sep 1998 A
5800482 Pomeranz et al. Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5827216 Igo et al. Oct 1998 A
5836947 Fleischman et al. Nov 1998 A
5840030 Ferek-Petric et al. Nov 1998 A
5844349 Oakley et al. Dec 1998 A
5846187 Wells et al. Dec 1998 A
5846191 Wells et al. Dec 1998 A
5849028 Chen Dec 1998 A
5860974 Abele Jan 1999 A
5871523 Fleischman et al. Feb 1999 A
5871525 Edwards et al. Feb 1999 A
5873845 Cline et al. Feb 1999 A
5876398 Mulier et al. Mar 1999 A
5876399 Chia et al. Mar 1999 A
5879295 Li et al. Mar 1999 A
5879296 Ockuly et al. Mar 1999 A
5881732 Sung et al. Mar 1999 A
5882346 Pomeranz et al. Mar 1999 A
5885278 Fleischman Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891095 Eggers et al. Apr 1999 A
5893848 Negus et al. Apr 1999 A
5895417 Pomeranz et al. Apr 1999 A
5897553 Mulier Apr 1999 A
5897554 Chia et al. Apr 1999 A
5899898 Arless et al. May 1999 A
5899899 Arless et al. May 1999 A
5902289 Swartz et al. May 1999 A
5902328 LaFontaine et al. May 1999 A
5904711 Flom et al. May 1999 A
5906580 Kline-Schoder et al. May 1999 A
5906587 Zimmon May 1999 A
5906606 Chee et al. May 1999 A
5906613 Mulier et al. May 1999 A
5908029 Knudson et al. Jun 1999 A
5913854 Maguire et al. Jun 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5916214 Cosio et al. Jun 1999 A
5921924 Avitall Jul 1999 A
5921982 Lesh et al. Jul 1999 A
5927284 Borst et al. Jul 1999 A
5928191 Houser et al. Jul 1999 A
5931810 Grabek Aug 1999 A
5931848 Saadat Aug 1999 A
5954661 Greenspon et al. Sep 1999 A
5971980 Sherman Oct 1999 A
5971983 Lesh Oct 1999 A
5993447 Blewett et al. Nov 1999 A
6007499 Martin et al. Dec 1999 A
6012457 Lesh Jan 2000 A
6016811 Knopp et al. Jan 2000 A
6033403 Tu et al. Mar 2000 A
6042556 Beach et al. Mar 2000 A
6063081 Mulier et al. May 2000 A
6071279 Whayne et al. Jun 2000 A
6071280 Edwards et al. Jun 2000 A
6088894 Oakley Jul 2000 A
6096037 Mulier Aug 2000 A
6113592 Taylor Sep 2000 A
6117101 Diederich et al. Sep 2000 A
6120496 Whayne et al. Sep 2000 A
6142993 Whayne et al. Nov 2000 A
6142994 Swanson et al. Nov 2000 A
6152920 Thompson et al. Nov 2000 A
6161543 Cox et al. Dec 2000 A
6165174 Jacobs et al. Dec 2000 A
6179824 Eggers et al. Jan 2001 B1
6217528 Koblish et al. Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6231518 Grabek et al. May 2001 B1
6235024 Tu May 2001 B1
6237605 Vaska et al. May 2001 B1
6238347 Nix et al. May 2001 B1
6238393 Mulier May 2001 B1
6245061 Panescu et al. Jun 2001 B1
6245064 Lesh et al. Jun 2001 B1
6245065 Panescu et al. Jun 2001 B1
6251092 Qin et al. Jun 2001 B1
6251128 Knopp et al. Jun 2001 B1
6270471 Hechel et al. Aug 2001 B1
6293943 Panescu et al. Sep 2001 B1
6296619 Brisken et al. Oct 2001 B1
6302880 Schaer Oct 2001 B1
6311692 Vaska et al. Nov 2001 B1
6312383 Lizzi et al. Nov 2001 B1
6314962 Vaska et al. Nov 2001 B1
6314963 Vaska et al. Nov 2001 B1
6325797 Stewart et al. Dec 2001 B1
6327505 Medhkour et al. Dec 2001 B1
6328736 Mulier Dec 2001 B1
6332881 Carner et al. Dec 2001 B1
6358248 Mulier Mar 2002 B1
6361531 Hissong Mar 2002 B1
6364876 Erb et al. Apr 2002 B1
6368275 Sliwa et al. Apr 2002 B1
6371955 Fuimaono et al. Apr 2002 B1
6383151 Diederich et al. May 2002 B1
6385472 Hall et al. May 2002 B1
6398792 O'Connor Jun 2002 B1
6409722 Hoey Jun 2002 B1
6413254 Hissong et al. Jul 2002 B1
6419648 Vitek et al. Jul 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6430426 Avitall Aug 2002 B2
6440130 Mulier Aug 2002 B1
6443952 Mulier et al. Sep 2002 B1
6447507 Bednarek et al. Sep 2002 B1
6461314 Pant et al. Oct 2002 B1
6461356 Patterson Oct 2002 B1
6464700 Koblish et al. Oct 2002 B1
6471697 Lesh Oct 2002 B1
6471698 Edwards et al. Oct 2002 B1
6474340 Vaska et al. Nov 2002 B1
6475216 Mulier Nov 2002 B2
6477396 Mest et al. Nov 2002 B1
6484727 Vaska et al. Nov 2002 B1
6488680 Francischelli Dec 2002 B1
6502575 Jacobs et al. Jan 2003 B1
6514250 Jahns Feb 2003 B1
6527767 Wang et al. Mar 2003 B2
6537248 Mulier Mar 2003 B2
6537272 Christopherson et al. Mar 2003 B2
6558382 Jahns May 2003 B2
6584360 Francischelli Jun 2003 B2
C15697536 Eggers et al. Jun 2003
6585732 Mulier Jul 2003 B2
6605084 Acker et al. Aug 2003 B2
6610055 Swanson et al. Aug 2003 B1
6610060 Mulier Aug 2003 B2
6613048 Mulier Sep 2003 B2
6645199 Jenkins et al. Nov 2003 B1
6648883 Francischelli Nov 2003 B2
6656175 Francischelli Dec 2003 B2
6663627 Francischelli Dec 2003 B2
6692450 Coleman Feb 2004 B1
6699240 Francischelli Mar 2004 B2
6702811 Stewart et al. Mar 2004 B2
6706038 Francischelli Mar 2004 B2
6706039 Mulier Mar 2004 B2
6716211 Mulier Apr 2004 B2
6736810 Hoey May 2004 B2
6755827 Mulier Jun 2004 B2
6764487 Mulier Jul 2004 B2
6773433 Stewart et al. Aug 2004 B2
6776780 Mulier Aug 2004 B2
6807968 Francischelli Oct 2004 B2
6827715 Francischelli Dec 2004 B2
6849073 Hoey Feb 2005 B2
6858028 Mulier Feb 2005 B2
6887238 Jahns et al. May 2005 B2
6899711 Stewart et al. May 2005 B2
6911019 Mulier Jun 2005 B2
6916318 Francischelli Jul 2005 B2
6936046 Hissong Aug 2005 B2
6949097 Stewart et al. Sep 2005 B2
6949098 Mulier Sep 2005 B2
6960205 Jahns Nov 2005 B2
6962589 Mulier et al. Nov 2005 B2
7156845 Mulier et al. Jan 2007 B2
20030045872 Jacobs Mar 2003 A1
20030144656 Ocel Jul 2003 A1
20030191462 Jacobs Oct 2003 A1
20030216724 Jahns Nov 2003 A1
20040015106 Coleman Jan 2004 A1
20040015219 Francischelli Jan 2004 A1
20040044340 Francischelli Mar 2004 A1
20040049179 Francischelli Mar 2004 A1
20040078069 Francischelli Apr 2004 A1
20040082948 Stewart et al. Apr 2004 A1
20040087940 Jahns May 2004 A1
20040092926 Hoey May 2004 A1
20040138621 Jahns Jul 2004 A1
20040138656 Francischelli Jul 2004 A1
20040143260 Francischelli Jul 2004 A1
20040186465 Francischelli Sep 2004 A1
20040215183 Hoey Oct 2004 A1
20040220560 Briscoe Nov 2004 A1
20040236322 Mulier Nov 2004 A1
20040267326 Ocel Dec 2004 A1
20050010095 Stewart Jan 2005 A1
20050033280 Francischelli Feb 2005 A1
20050090815 Francischelli Apr 2005 A1
20050143729 Francischelli Jun 2005 A1
20050165392 Francischelli Jul 2005 A1
20050209564 Bonner Sep 2005 A1
20050267454 Hissong Dec 2005 A1
20060009756 Francischelli Jan 2006 A1
20060009759 Chrisitian Jan 2006 A1
Non-Patent Literature Citations (41)
Entry
Chitwood, “Will C. Sealy, MD: The Father of Arrhythmia Surgery—The Story of the Fisherman with a Fast Pulse,” Annals of Thoracic Surgery 58:1228-1239, 1994.
Gallagher et al., “Cryosurgical Ablation of Accessory Atrioventrical Connections: A Method for Correction of the Pre-excitation Syndrome,” Circulation 55(3): 471-479, 1977.
Sealy, “Direct Surgical Treatment of Arrhythmias: The Last Frontier in Surgical Cardiology,” Chest 75(5): 536-537, 1979.
Sealy, “The Evolution of the Surgical Methods for Interruption of Right Free Wall Kent Bundles,” The Annals of Thoracic Surgery 36(1): 29-36, 1983.
Guiraudon et al., “Surgical Repair of Wolff-Parkinson-White Syndrome: A New Closed-Heart Techique,” The Annals of Thoracic Surgery 37(1): 67-71, 1984.
Klein et al., “Surgical Correction of the Wolff-Parkinson-White Syndrome in the Closed Heart Using Cryosurgery: A Simplified Approach,” JACC 3(2): 405409, 1984.
Randall et al., “Local Epicardial Chemical Ablation of Vagal Input to Sino-Atrial and Atrioventricular Regions of the Canine Heart,” Journal of the Autonomic Nervous System 11:145-159, 1984.
Guiraudon et al., “Surgical Ablation of Posterior Septal Accessory Pathways in the Wolf-Parkinson-White Syndrome by a Closed Heart Technique,” Journal Thoracic Cardiovascular Surgery 92:406-413, 1986.
Gallagher et al., “Surgical Treatment of Arrhythmias,” The American Journal of Cardiology 61:27A-44A, 1988.
Mahomed et al., “Surgical Division of Wolff-Parkinson-White Pathways Utilizing the Closed-Heart Technique: A 2-Year Experience in 47 Patients,” The Annals of Thoracic Surgery 45(5): 495-504, 1988.
Cox et al., Surgery for Atrial Fibrillation; Seminars in Thoracic and Cardiovascular Surgery., vol. 1, No. 1 (Jul. 1989) pp. 67-73.
Bredikis and Bredikis; Surgery of Tachyarrhythmia: Intracardiac Closed Heart Cryoablation; PACE, vol. 13, pp. 1980-1984.
McCarthy et al., “Combined Treatment of Mitral Regurgitation and Atrial Fibrillation with Valvuloplasty and the Maze Procedure,” The American Journal of Cardiology 71: 483-486, 1993.
Yamauchi et al. “Use of Intraoperative Mapping to Optimize Surgical Ablation of Atrial Flutter,” The Annals of Thoracic Surgery 56: 337-342, 1993.
Graffigna et al., “Surgical Treatment of Wolff-Parkinson-White Syndrome: Epicardial Approach Without the Use of Cardiopulmonary Bypass,” Journal of Cardiac Surgery 8: 108-116, 1993.
Siefert et al., “Radiofrequency Maze Ablation for Atrial Fibrillation,” Circulation 90(4): I-594.
Surgical treatment of atrial fibrillation: a review; Europace (2004) 5, S20-S29.
Elvan et al., “Radiofrequency Catheter Ablation of the Atria Reduces Inducibility and Duration of Atrial Fibrillation in Dog,” Circulation 91: 2235-2244, 1995.
Cox et al., “Modification of the Maze Procedure for Atrial Flutter and Atrial Fibrillation. I. Rational and Surgical Results,” The Journal of Thoracic Cardiovascular Surgery 110: 473-484, 1995.
Cox, “The Maze III Procedure for Treatment of Atrial Fibrillation,” Sabiston DC, ed Atlas of Cardiothoracic Surgery, Philadelphia: WB Saunders: 460-475, 1994.
Sueda et al., “Simple Left Atrial Procedure for Chronic Atrial Fibrillation Associated with Mitral Valve Disease,” The Annals of Thoracic Surgery 62(6): 1796-1800, 1996.
Tsui et al., “Maze 3 for Atrial Fibrillation: Two Cuts Too Few?” PACE 17: 2163-2166, 1994.
Kosakai et al., “Cox Maze Procedure for Chronic Atrial Fibrillation Associated with Mitral Valve Disease,” The Journal of Thoracic Cardiovascular Surgery 108: 1049-1055, 1994.
Cox et al., “The Surgical Treatment of Atrial Fibrillation, IV Surgical Technique,” J of Thorac Cardiovasc Surg, 1991: 101: 584-593.
Nardella, “Radio Frequency Energy and Impedance Feedback,” SPIE vol. 1068, Catheter Based Sensing and Imaging Technology (1989).
Avitall et. al., “A Thoracoscopic Approach to Ablate Atrial Fibrillation Via Linear Radiofrequency Lesion Generation on the Epicardium of Both Atria;” PACE; Apr. 1996;19(Part II):626,#241.
Sie et al., “Radiofrequency Ablation of Atrial Fibrillation in Patients Undergoing Mitral Valve Surgery. First Experience,” Circulation (Nov. 1996) 96:450,I-675,#3946.
Sie et al., “Radiofrequency Ablation of Atrial Fibrillation in Patients Undergoing Valve Surgery,” Circulation (Nov. 1997) 84:I450,#2519.
Cox, “Evolving Applications of the Maze Procedure for Atrial Fibrillation,” Ann Thorac Surg, 1993;55:578-580.
Cox et al. “Five-Year Experience with the Maze Procedure for Atrial Fibrillation,” Ann Thorac Surg, 1993; 56:814-824.
Avitall et al., “New Monitoring Criteria for Transmural Ablation of Atrial Tissues,” Circulation, 1996;94(Supp 1):I-493,#2889.
Cox et al., “An 8 1/2 Year Clinical Experience with Surgery for Atrial Fibrillation,” Annals of Surgery, 1996;224(3):267-275.
Haissaguerre et al., “Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation in Humans: Elaboration of a procedure based on electrophysiological data,” Nonpharmacological Management of Atrial Fibrillation, 1997 pp. 257-279.
Haissaguerre at al., “Right and Left Atrial Radiofrequency Catheter Therapy of Paroxysmal Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology, 1996;7(12):1132-1144.
Haissaguerre et al., “Role of Catheter Ablation for Atrial Fibrillation,” Current Opinion in Cardiology, 1997;12:18-23.
Kawaguchi et al., “Risks and Benefits of Combined Maze Procedure for Atrial Fibrillation Associated with Organic Heart Disease,” JACC, 1996;28(4):985-990.
Cox, et al., “Perinodal cryosurgery for atrioventricular node reentry tachycardia in 23 patients,” Journal of Thoracic and Cardiovascular Surgery, 99:3, Mar. 1990, pp. 440-450.
Cox, “Anatomic-Electrophysiologic Basis for the Surgical Treatment of Refractory Ischemic Ventricular Tachycardia,” Annals of Surgery, Aug. 1983; 198:2;119-129.
Williams, et al., “Left atrial isolation,” J Thorac Cardiovasc Surg; 1980; 80: 373-380.
Sueda et al., “Simple Left Atrial Procedure for Chronic Atrial Fibrillation Associated with Mitral Valve Disease,” Ann Thorac Surg, 1996;62:1796-1800.
Sueda et al., “Efficacy of a Simple Left Atrial Procedure for Chronic Atrial Fibrillation in Mitral Valve Operations,” Ann Thorac Surg, 1997;63:1070-1075.
Related Publications (1)
Number Date Country
20080103497 A1 May 2008 US
Provisional Applications (1)
Number Date Country
60091929 Jul 1998 US
Continuations (5)
Number Date Country
Parent 11636331 Dec 2006 US
Child 11966769 US
Parent 11229414 Sep 2005 US
Child 11636331 US
Parent 10754768 Jan 2004 US
Child 11229414 US
Parent 09865591 May 2001 US
Child 10754768 US
Parent 09347971 Jul 1999 US
Child 09865591 US